Clinical Trials Browser

Phase 1 × Esophageal Neoplasms × Trastuzumab × Clear all

NCT05187182 2026-03-18

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

Phase 1 Recruiting

42 enrolled

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT05143970 2024-03-20

CHANCES

Phase 1 Unknown

27 enrolled

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT01705340 2013-09-30

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

Phase 1 Terminated

60 enrolled

BreastGastrointestinal

Breast Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Breast Neoplasms, Male

NCT00004074 2013-02-28

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Phase 1 Completed

15 enrolled

BreastEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Thyroid Cancer, Papillary, Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Vipoma, Esophageal Neoplasms, Fallopian Tube Neoplasms, Gallbladder Neoplasms, Glucagonoma, Carcinoma, Hepatocellular, Insulinoma, Neoplasms, Unknown Primary, Pancreatic Neoplasms, Parathyroid Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Somatostatinoma, Stomach Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Gastrinoma, Pleural Effusion, Malignant, Endometrial Neoplasms, Adenocarcinoma, Follicular, Adrenocortical Carcinoma, Carcinoma, Islet Cell, Carcinoma, Medullary, Breast Neoplasms, Male, Inflammatory Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT00005842 2013-02-11

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

Phase 1 Completed

24 enrolled

BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Thyroid Cancer, Papillary, Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Vipoma, Esophageal Neoplasms, Gallbladder Neoplasms, Glucagonoma, Carcinoma, Hepatocellular, Insulinoma, Neoplasms, Neoplasms, Unknown Primary, Pancreatic Neoplasms, Parathyroid Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Somatostatinoma, Stomach Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Gastrinoma, Pleural Effusion, Malignant, Endometrial Neoplasms, Adenocarcinoma, Follicular, Adrenocortical Carcinoma, Carcinoma, Islet Cell, Carcinoma, Medullary, Breast Neoplasms, Male, Meningeal Carcinomatosis, Inflammatory Breast Neoplasms, Thyroid Carcinoma, Anaplastic